MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
Manuela Ferracin(University of Ferrara), Antonio Cuneo(Arcispedale Sant'Anna), Francesco Cavazzini(Arcispedale Sant'Anna), Laura Lupini(University of Ferrara), Andrea Grilli(University of Ferrara), Lara Rizzotto, Elena Saccenti(University of Ferrara), Angelo Veronese(University of Ferrara), Cristiano De Angeli(University of Ferrara), Barbara Zagatti(University of Ferrara), Maria Ciccone(Arcispedale Sant'Anna), Massimo Negrini(University of Ferrara)
Cited by 121
Related Papers
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells
|Experimental Hematology|2008|254
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|215
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
|Blood|2019|215
Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus
|Cancer Research|2010|213